Getinge operates three segments: acute care therapies (52% of revenue), surgical workflows (34%), and life sciences (14%). The Americas account for 45% of sales with the US representing 33%, Asia-Pacific 25%, and Europe, Middle East, and Africa the remaining 30%, providing geographic diversification and resilience.
Cyborg Score Rationale
The company reported 2024 revenue of $3.3B with a net income decline of 32.1% and net profit margin decline of 37.9%. Despite margin pressures and operational headwinds, established market leadership and strategic acquisitions support medium-term recovery potential.
Top Insights
2024 revenue increased 9.21% to 34.76 billion SEK, demonstrating resilience in core markets
Getinge acquired Paragonix Technologies on September 11, 2024, expanding organ transport capabilities
The company operates manufacturing facilities across nine countries including France, China, Germany, Poland, Sweden, Turkey, the Netherlands, UK, and US
In 2025, Getinge expanded Servo-c ventilator offerings to neonatal patients supporting preterm birth babies
Named Competitors
Siemens Healthineers — Healthcare diagnostics and medical technology
Drägerwerk — Medical technology and safety equipment
Philips Healthcare — Connected care and diagnostic systems
Stryker — Surgical equipment and orthopedic devices
Recent Developments
(February 2025) DPTE-FLEX Alpha Port launch enabling gloveless component transfer in pharmaceutical production
(January 2025) Cincinnati Children's Hospital selected as anesthesia fleet provider
(September 2024) Acquisition of Paragonix Technologies for organ transport solutions
Open the full interactive Getinge AB report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.